Literature DB >> 1677312

Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/neu gene amplification.

J P Zheng1, W R Robinson, T Ehlen, M C Yu, L Dubeau.   

Abstract

We examined the frequencies of loss of heterozygosity at 13 different loci distributed on 9 chromosomes in 30 human ovarian carcinomas. The same tumors were also examined for the presence of amplification of the HER-2/neu and H-ras protooncogenes. The results confirmed earlier findings that losses of heterozygosity occurred at nonrandom frequencies on chromosomes 3, 6, and 11 in these tumors. None of the tumors examined showed amplification at the H-ras locus. The HER-2/neu gene, however, was amplified in approximately one-third of the tumors, in agreement with earlier studies from other laboratories. We subdivided our tumor specimens according to their histological grades, which can be regarded as representing different stages of tumor progression. Losses of heterozygosity on chromosomes 3 or 11 were not seen in low grade lesions, although they were present in most of the high grade tumors examined. Losses of heterozygosity on chromosome 6 as well as HER-2/neu amplification, in contrast, were present in several low grade tumors and were not more frequent in high grade lesions. We conclude that the latter two abnormalities are associated with cellular functions involved at earlier stages of ovarian tumor development, whereas inactivation of genes on chromosome 3 or 11 is associated with later steps that may be incompatible with the well differentiated phenotype.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677312

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.

Authors:  Kimberly J Bussey; Koei Chin; Samir Lababidi; Mark Reimers; William C Reinhold; Wen-Lin Kuo; Fuad Gwadry; Hosein Kouros-Mehr; Jane Fridlyand; Ajay Jain; Colin Collins; Satoshi Nishizuka; Giovanni Tonon; Anna Roschke; Kristen Gehlhaus; Ilan Kirsch; Dominic A Scudiero; Joe W Gray; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

2.  Study of numerical aberrations of chromosome 1 by fluorescent in situ hybridization and DNA content by densitometric analysis on (pre)-malignant cervical lesions.

Authors:  P Segers; S Haesen; P Castelain; J J Amy; P De Sutter; P Van Dam; M Kirsch-Volders
Journal:  Histochem J       Date:  1995-01

3.  Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization.

Authors:  T Ishikawa; M Kobayashi; M Mai; T Suzuki; A Ooi
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

4.  Origins of heterogeneous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential, and fully malignant components.

Authors:  N G Wolf; F W Abdul-Karim; N J Schork; S Schwartz
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

5.  Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas.

Authors:  D L Persons; L C Hartmann; J F Herath; T J Borell; W A Cliby; G L Keeney; R B Jenkins
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

6.  Loss of heterozygosity on chromosome 6q27 and p53 mutations in epithelial ovarian cancer.

Authors:  M Suzuki; S Saito; Y Saga; M Ohwada; I Sato
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

7.  A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.

Authors:  A K Godwin; L Vanderveer; D C Schultz; H T Lynch; D A Altomare; K H Buetow; M Daly; L A Getts; A Masny; N Rosenblum
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

8.  An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Kozue Suzuki; Masashi Takano; Seiichi Tamai; Osamu Matsubara
Journal:  Virchows Arch       Date:  2009-08-05       Impact factor: 4.064

Review 9.  The cell of origin of ovarian epithelial tumours.

Authors:  Louis Dubeau
Journal:  Lancet Oncol       Date:  2008-12       Impact factor: 41.316

10.  Polymerase chain reaction allelotyping of human ovarian cancer.

Authors:  R J Osborne; V Leech
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.